Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13314812 | 1.00 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| Formic Acid SCHEMBL3603162 | 0.96 | RAB9A (0.44) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL3533425 | 0.89 | RAB9A (0.50) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL13314816 | 0.89 | RAB9A (0.50) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL13314905 | 0.84 | RAB9A (0.52) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL6208532 | 0.83 | RAB9A (0.40) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL13314888 | 0.83 | RAB9A (0.48) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL13314811 | 0.81 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL3534831 | 0.81 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL3538335 | 0.80 | ADRA2A (0.41) | RAB9ASMN1; SMN2NPC1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | claimed |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2015120446-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULENESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-08-13 | — | — | WO | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | RAB9A 4051/4885SMN1; SMN2 399/4885NPC1 3023/4885 |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | HCRTR2, HCRTR1, NPSR1 | RAB9A 3671/4885SMN1; SMN2 1337/4885NPC1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.